Octagon Capital Advisors LP: MIRUM PHARMACEUTICALS INC (MIRM): Quarterly 13F Position History
As of Q1 2026, Octagon Capital Advisors LP reported 338,900 shares of MIRUM PHARMACEUTICALS INC (MIRM), worth $31.3M and representing 3.5% of its 13F equity book. Quarter-over-quarter share count change: + 338,900 (re-initiated) . The position first appeared in Q3 2022 and has been disclosed across 15 13F-HR filings in Pactolio's tracked window.
- 338,900Shares Held (Latest Filing)
- $31.3MReported Market Value (Latest Filing)
- 3.5%Portfolio Weight (% of 13F Equity Book)
- +338,900Quarter-over-Quarter Share Change
- +$31.3MQuarter-over-Quarter Value Change
- 338,900Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 15 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 338,900 | +338,900 | — | $31.3M | 3.5% | $92.4 |
| Q4 2025 | 0 | 0 | — | $0 | 0.0% | — |
| Q3 2025 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2025 | 0 | 0 | — | $0 | 0.0% | — |
| Q1 2025 | 0 | 0 | — | $0 | 0.0% | — |
| Q4 2024 | 0 | 0 | — | $0 | 0.0% | — |
| Q3 2024 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2024 | 0 | 0 | — | $0 | 0.0% | — |
| Q1 2024 | 0 | 25,000 | -100.0% | $0 | 0.0% | — |
| Q4 2023 | 25,000 | +25,000 | — | $738.0K | 0.1% | $29.5 |
| Q3 2023 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2023 | 0 | 0 | — | $0 | 0.0% | — |
| Q1 2023 | 0 | 100,000 | -100.0% | $0 | 0.0% | — |
| Q4 2022 | 100,000 | 0 | — | $1.9M | 0.3% | $19.5 |
| Q3 2022 | 100,000 | — | — | $2.1M | 0.4% | $21.0 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Octagon Capital Advisors LP first disclose a MIRM position in 13F-HR filings?
Octagon Capital Advisors LP first reported MIRUM PHARMACEUTICALS INC (MIRM) on its 13F-HR filing for the period ending 2022-09-30 (Q3 2022). The position has appeared on 15 reported quarters within Pactolio's tracked window.
What was Octagon Capital Advisors LP's most recent quarter-over-quarter share-count change in MIRM?
Between Q4 2025 and Q1 2026, Octagon Capital Advisors LP added 338,900 shares of MIRM (re-initiated), bringing the total reported position to 338,900 shares at a market value of $31.3M.
Does the implied price-per-share represent Octagon Capital Advisors LP's cost basis in MIRM?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.